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Research Altered placental expression of PAPPA2 does not 
affect birth weight in mice
Pamela K Wagner and Julian K Christians*
Abstract
Background: Pregnancy-associated plasma protein A2 (PAPPA2) is an insulin-like growth factor binding protein (IGFBP) 
protease expressed in the placenta and upregulated in pregnancies complicated by pre-eclampsia. The mechanism 
linking PAPPA2 expression and pre-eclampsia and the consequences of altered PAPPA2 expression remain unknown. 
We previously identified PAPPA2 as a candidate gene for a quantitative trait locus (QTL) affecting growth in mice and in 
the present study examined whether this QTL affects placental PAPPA2 expression and, in turn, placental or embryonic 
growth.
Methods: Using a line of mice that are genetically homogenous apart from a 1 megabase QTL region containing the 
PAPPA2 gene, we bred mice homozygous for alternate QTL genotypes and collected and weighed placentae and 
embryos at E12.5. We used quantitative RT-PCR to measure the mRNA levels of PAPPA2, as well as mRNA levels of 
IGFBP-5 (PAPPA2's substrate), and PAPPA (a closely related IGFBP protease) to examine potential feedback and 
compensation effects. Western blotting was used to quantify PAPPA2 protein. Birth weight was measured in 
pregnancies allowed to proceed to parturition.
Results: PAPPA2 mRNA and protein expression levels in the placenta differed by a factor of 2.5 between genotypes, but 
we did not find a significant difference between genotypes in embryonic PAPPA2 mRNA levels. Placental IGFBP-5 and 
PAPPA mRNA expression levels were not altered in response to PAPPA2 levels, and we could not detect IGFBP-5 protein 
in the placenta by Western blotting. The observed difference in placental PAPPA2 expression had no significant effect 
on placental or embryonic mass at mid-gestation, birth weight or litter size.
Conclusions: Despite a significant difference between genotypes in placental PAPPA2 expression similar in magnitude 
to the difference between pre-eclamptic and normal placentae previously reported, we observed no difference in 
embryonic, placental or birth weight. Our results suggest that elevated PAPPA2 levels are a consequence, rather than a 
cause, of pregnancy complications.
Background
Insulin-like growth factors (IGFs) play a pivotal role in
fetal and placental development [1]. The bioavailability of
the IGFs is regulated by six IGF binding proteins
(IGFBPs), and release of IGFs and subsequent IGF signal-
ling is achieved primarily through cleavage of the IGFBPs
by proteases [2-4]. Pregnancy-associated plasma protein
A (PAPPA) is an IGFBP protease expressed at high levels
by the placenta, and is the main enzyme responsible for
the cleavage of IGFBP-4 in this tissue [5,6]. Circulating
levels of PAPPA are elevated dramatically during preg-
nancy, and prenatal testing for low levels of PAPPA in
maternal serum is currently used to screen for Down's
syndrome and other aneuploidies [7,8]. Abnormally low
levels of PAPPA are also associated with preterm delivery
[9], pre-eclampsia [9,10], intrauterine growth restriction
(IUGR) [11,12], and other adverse outcomes such as still-
birth [9].
Pregnancy-associated plasma protein A2 (PAPPA2),
also known as pappalysin-2 and PAPP-E [13], is another
IGFBP protease produced at high levels by the placenta
that has received much less study. PAPPA2 is 45% identi-
cal to PAPPA at the amino acid level [14] and, in addition
to similarity in sequence, PAPPA and PAPPA2 have simi-
lar substrates: PAPPA cleaves IGFBP-4 and perhaps
IGFBP-2 and IGFBP-5 [15], while PAPPA2 is only known
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to cleave IGFBP-5 [14]. Recently, PAPPA2 has been
shown to be responsible for the IGFBP-5 proteolytic
activity of pregnancy plasma, resulting in increased IGF
bioavailability [16]. Furthermore, four other studies have
found PAPPA2 to be upregulated in placentae from preg-
nancies complicated by pre-eclampsia and a pre-eclamp-
sia-like syndrome, HELLP (Hemolytic anemia, Elevated
Liver enzymes, and Low Platelet count) [17-20]. However,
it is not clear whether PAPPA2 expression is upregulated
to compensate for abnormal placentation or whether ele-
vated PAPPA2 levels cause abnormal placental develop-
ment, leading to hypertensive disorders [21]. Elevated
P APP A2 levels might be expected to increase IGFBP -5
proteolysis and so increase IGF availability and placental
development. However, Winn et al. [20] suggested that
increased PAPPA2 levels could reduce stimulatory effects
of IGFBP-5, and so reduce cytotrophoblast invasion of
the decidua, an important step in placental development.
IGFBP signalling is complex, and IGFBP-5 has been
shown to have stimulatory and IGF-independent roles
[22]. An animal model is therefore needed to elucidate
the functional role of PAPPA2 during pregnancy. Recent
work has shown that PAPPA2 is expressed at high levels
in the murine placenta and that it is expressed in along
the fetal-maternal interface of the placenta in both mouse
and human [23], suggesting that the mouse may be a suit-
able model for studying the placental roles of PAPPA2.
In light of the recent work that found P APP A2 to be
upregulated in human pre-eclamptic placentae [17-20],
we sought to investigate the phenotypic consequences of
altered placental PAPPA2 expression in mice. To do this,
we examined natural variation in the PAPPA2 gene that
has previously been associated with postnatal growth in
mice: quantitative trait locus (QTL) mapping revealed
that a chromosomal region containing the PAPPA2 gene
affects body size [24]. The QTL region contains only four
genes, including PAPPA2, and affects the circulating lev-
els of IGFBP-5, PAPPA2's substrate [24], suggesting that
PAPPA2 is a strong candidate gene for this QTL.
The goal of the present study was to examine whether
this QTL affects placental PAPPA2 expression in mice
a nd,  if  so ,  w het he r  al t er ed e x pr es si on of  t his  ge ne  has
phenotypic consequences. Pre-eclampsia results from
abnormal placentation combined with risk factors that
predispose the mother to hypertension [25-27]. Since
PAPPA2 is expressed at high levels in the placenta, we
predicted that altered PAPPA2 expression might influ-
ence placental development, but not necessarily the risk
of hypertension. Therefore, we focused on placental
weight, embryonic weight and birth weight as phenotypic
outcomes since intrauterine growth restriction is also
caused by abnormal placentation and is often associated
with pre-eclampsia [26,28]. Furthermore, Nishizawa et al.
[18] found negative correlations between birth weight
and placental weight and circulating PAPPA2 levels when
combining data from normal and pre-eclamptic pregnan-
cies. We examined the effects of variation in the QTL
region using a line of mice that is genetically homogenous
but segregates for a 1 megabase (MB) region containing
the QTL [24]. Although altered placental expression of
PAPPA2 is not expected to be the mechanism underlying
the postnatal growth QTL described previously, variation
in the PAPPA2 gene could have pleiotropic effects on pre-
natal and postnatal growth.
Methods
Mice and sample collection
In previous work, we introgressed the C57BL/6 allele of a
chromosome 1 QTL into the DBA/2 background to pro-
duce a line segregating for an approximately 1-MB region
containing the QTL [24]. This line is currently at back-
cross generation 12. The mice used in this study were all
obtained from matings between mice heterozygous for
the QTL region, i.e., the grandparents of all of the
embryos and pups studied were of the same genotype.
These matings produced litters in which offspring varied
for QTL genotype, and we paired mice of the same
homozygous QTL genotype (i.e. homozygous C57BL/6 or
homozygous DBA/2) to produce placentae and embryos
homozygous for the alternate genotypes. Females were
checked for seminal plugs the morning following pairing,
and plugged females were euthanized with CO2 twelve
days later (embryonic day 12.5). Since the abnormal pla-
centation that is thought to cause pre-eclampsia and
intrauterine growth restriction occurs early in pregnancy
[26], we wanted to sample placentae as early in pregnancy
as possible, while ensuring that individual placentae and
embryos would be sufficiently large for mRNA extrac-
tion. We therefore chose to collect females at embryonic
day 12.5. Preliminary data indicated that placental
PAPPA2 mRNA levels were similar at E10.5, E12.5 and
E18.5 (data not shown), and placental PAPPA2 protein
levels have been found to be similar from E11.5 to E15.5
by immunohistochemistry [23].
Placentae and embryos were dissected while immersed
in 10× PBS treated with DEPC, then weighed. The num-
ber of embryos and spontaneous abortions were counted;
aborted embryos were characterized by a small region of
uterine horn containing dark tissue, without any sign of
placenta or embryo. Half of the placenta and embryo
samples were stored in RNAlater® (Ambion, Foster City,
CA) for quantification of mRNA levels by quantitative
real-time PCR (qRT-PCR), and the other half were frozen
at -80°C for quantification of protein levels by Western
blotting.
To determine birth weight, females were not checked
for plugs, but were instead left with males, checked daily
three to four and a half hours after the lights were turnedWagner and Christians Reproductive Biology and Endocrinology 2010, 8:90
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on, and new pups were weighed. In addition to the mea-
surement of birth weight in pups from the homozygous
matings described above, we also weighed pups from
heterozygous matings, where genotype varied within lit-
ters. We anaesthetized the newborn offspring of
heterozygous pairings using isofluorane, and collected 2
mm of tail tissue for genotyping. We genotyped pups by
PCR using two microsatellite markers that delimit the
QTL region (D1Icp1 primers: CTTTGACAGGAGTG-
GCTGAT and TTGAAGGCTAGTCTCTCTACTGG;
D1Icp9 primers: TTCCAAATCCTGCCACTATC and
CAAACATCCAGTCCTTCTCC). All work was carried
out in accordance with the guidelines of the Canadian
Council on Animal Care and approved by the SFU Ani-
mal Care committee (protocol 771B-05).
RNA isolation and qRT-PCR
Placentae and embryos were homogenized at room tem-
perature in 600 μL of buffer RLT (Qiagen, Ontario, Can-
ada) using pestles. The samples were further
homogenized using Qiashredders (Qiagen, Ontario, Can-
ada) and total RNA was extracted using the RNeasy Mini
kit (Qiagen, Ontario, Canada) according to the manufac-
turer's instructions. RNA concentration was determined
using a Nanodrop spectrophotometer (Thermo Fischer
Scientific Inc. Waltham, MA), and each sample was
diluted to a final concentration of 50 ng/μL. Reference
samples were prepared by combining aliquots of placen-
tal or embryonic RNA extracts, and separate reference
samples were used for placenta and embryo. These refer-
ence samples were included in every assay to account for
variation between assays. Quantitative real time (qRT)
PCR was performed to compare levels of PAPPA2 mRNA
between the two different genotypes. Where significant
differences in PAPPA2 levels were observed, we also com-
pared mRNA levels of IGFBP-5, the substrate of PAPPA2,
and PAPPA, a closely related protease, to test for feed-
back or compensation effects. Levels of β-actin were also
measured and used as a reference to standardize the val-
ues of the other genes (see Table 1 for primer and probe
sequences). The qScript 1-step qRT-PCR kit (Quanta
Biosciences Inc. Gaithersburg, MD) was used to reverse-
transcribe and amplify each sample. Reverse transcrip-
tion was carried out at 50°C for 30 minutes, followed by a
PCR activation step at 95°C for 15 minutes, followed by
amplification by 40 cycles of 1 minute at 94°C, 1 minute
at 55°C, and 1 minute at 72°C, and a final extension of 10
minutes at 72°C. Each reaction was performed using a
volume of 25 μL and contained 12.5 μL of reaction mix,
8.5 μL of RNA sample at 50 ng/μL, 1.5 μL (22.5 mM) of
each forward and reverse primer, 0.5 μL of reverse tran-
scriptase, and 0.5 μL (175 nM) of probe. Each sample was
analysed in triplicate for each gene, and in every assay,
one negative control and one reference sample were
included for each gene. Each sample was amplified for 40
cycles, and at each cycle, the amount of fluorescence was
quantified using a miniOpticon (Bio-Rad, Hercules, CA),
and the cycle at which the signal rose above a fixed
threshold (Ct) was determined. The products of the qRT-
PCR reactions were also run on 1% agarose gels to ensure
that only one band was present.
Protein extraction and Western blotting
Placentae and embryos were homogenized in 2 mL of T-
PER™ Tissue Protein Extraction Reagent (PIERCE, Rock-
ford, IL), incubated on ice for 7 minutes and then centri-
fuged at 10000 g for 5 minutes at 4°C. Complete protease
inhibitor cocktail (Roche Applied Sciences) was added to
the supernatant, which was then stored at -20°C.
Placental and embryonic samples containing 40 μg of
protein were mixed with 5× SDS loading buffer and
heated at 100°C for 10 minutes. 5 μL of PageRuler™
(#SM1811 Fermentas, Burlington, ON) was used as the
molecular weight marker for each gel. Samples were run
through a 4% stacking and 8% separating polyacrylamide
gel for 60 minutes. Gels were run in duplicate, with one
gel used to visualize total protein by staining with
EZBlue™ (Sigma Aldrich, St. Louis, MO) for one hour at
room temperature, followed by soaking in de-ionized,
distilled water overnight to remove excess stain. The
other gel was equilibrated in transfer buffer for 15 min-
utes and transferred onto a pure nitrocellulose membrane
(Bio-Rad, Hercules, CA) using the Trans-Blot® semi-dry
electrophoretic transfer cell (Bio-Rad, Hercules, CA).
After the transfer was complete, membranes were
blocked for one hour at room temperature in Odyssey
Blocking Buffer (Li-Cor Biosciences, Lincoln, Nebraska),
incubated for one hour at room temperature in a solution
Table 1: Primer and probe sequences used in qRT-PCR
Gene Forward Primer Reverse Primer Probe (contains fluorophore, 6-FAM™, on the 5' 
end and quencher, BHQ-1™, at the 3' end)
PAPPA2 GGGACAAGGAAGCTCTCAGT CAGGGATCATCACAGGATTC CATGCTTGGCCACACCAACATCATGATCCA
IGFBP-5 AAAGAGCTACGGCGAGCAAA AGTAGGTCTCTTCAGCCATCTC AGACTCTCGGGAACACGAGGAACCCA
PAPPA CACAATGGACTCTGTGATGCT TCTCCCTTCTAGGCAAAGGT TGGTTCCCACCCATCGATGG
β-actin CGTGAAAAGATGACCCAGAT GGTACGACCAGAGGCATACA ACCTTCAACACCCCAGCCATGTWagner and Christians Reproductive Biology and Endocrinology 2010, 8:90
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containing 1:500 monoclonal mouse anti-actin
(CLT9001; Cedarlane, Burlington ON) and 1:500 poly-
clonal goat-anti-human PAPPA2 antibody (AF1668; R&D
Systems, Minneapolis, MN) diluted in Odyssey Blocking
Buffer (Li-Cor Biosciences, Lincoln, NE) and 0.1%
Tween-20 (Sigma, ON, Canada), washed 4 times for 5
minutes each in filter-sterilized PBS containing 0.1%
Tween-20 at room temperature, and incubated in a solu-
tion containing 1:10000 fluorescently-labelled IRDye 800
anti-goat and IRDye 680 anti-mouse secondary antibod-
ies (Li-Cor Biosciences, Lincoln, NE) diluted in Odyssey
Blocking Buffer, 0.1% Tween-20 and 0.1% SDS for 45 min-
utes in the dark with gentle shaking. We performed all
subsequent steps in the dark to avoid breakdown of the
fluorescent dye. The membranes were again washed 4
times for 5 minutes each in filter-sterilized PBS contain-
ing 0.1% Tween-20 at room temperature, and rinsed with
filtered PBS. Both total protein gels and anti-PAPPA2
blotted nitrocellulose membranes were visualized using
the Odyssey infrared imaging system (Li-Cor Biosci-
ences, Lincoln, NE). The two secondary dyes fluoresce at
different wavelengths (anti-goat at 800 nm and anti-
mouse at 700 nm), so we were able to simultaneously
quantify the intensity of the PAPPA2 band (at approxi-
mately 250 kDa) and actin band (at approximately 40
kDa) on the same nitrocellulose membrane using the
Odyssey software. Although the anti-PAPPA2 antibody
we used was raised against human PAPPA2, previous
Western blotting of different murine tissues with this
antibody yielded results that correlated with mRNA lev-
els measured by qRT-PCR using primers and a probe
designed to target the mouse gene [23]. Furthermore, a
negative control Western blot in which the primary anti-
body was omitted produced no bands (data not shown).
Statistical analyses
We used the method of Pfaffl [29] to calculate mRNA
expression levels for PAPPA2, PAPPA and IGFBP5, rela-
tive to the reference sample described above, e.g., a value
of 1.5 indicates a sample has 50% more of a particular
transcript than the reference sample, correcting for β-
actin. To standardize PAPPA2 protein levels to actin, we
divided the intensity of the PAPPA2 band by the intensity
of the actin band, and then divided all of these ratios by
the mean ratio of all samples (to yield a mean of 1 for all
samples). RT-PCR and Western blotting data were analy-
sed by ANOVA using JMP, Version 7 (SAS Institute Inc.,
Cary, NC).
Results
Placental gene expression
We examined the expression of PAPPA2, its substrate
(IGFBP5) and a closely related gene (PAPPA) at 12.5 days
post-coitum in mice that differ in genotype at the 1 MB
QTL region, but are otherwise genetically homogeneous.
The mRNA levels of β-actin in the placenta did not differ
between genotypes (F(1,23) = 0.12, P = 0.73), indicating
that this housekeeping gene was suitable for standardiz-
ing samples. There was a significant effect of genotype on
placental PAPPA2 mRNA, with average PAPPA2 mRNA
levels in C57BL/6 genotype placentae approximately 2.5-
fold higher compared with DBA/2 genotype placentae
(F(1,24) = 39.8, P < 0.0001; Table 2, Fig. 1). This difference
was also significant when PAPPA2 mRNA levels were not
standardized using β-actin (data not shown). Western
blotting of placental samples with anti-PAPPA2 showed a
primary band of approximately 250 kDa, consistent with
previous work [23]; smaller bands may represent
degraded fragments of PAPPA2. Placental levels of
PAPPA2 protein differed between genotypes (F(1,18)  =
12.0, P = 0.003; Table 2, Fig. 2), and the difference was
similar in magnitude to that for placental mRNA expres-
sion. The difference at the protein level was significant
whether or not PAPPA2 protein levels were standardized
using quantification of actin (data not shown). Actin lev-
els quantified by Western blotting did not differ between
genotypes (F(1,18) = 0.16, P = 0.69). Including female age as
a covariate in the analyses of the effect of genotype did
not affect the results (data not shown). The placental
mRNA levels of PAPPA and IGFBP-5 did not differ
between genotypes (PAPPA: F(1,24)  = 0.56, P = 0.46;
IGFBP-5: F(1,24) = 0.08, P = 0.78; Table 2). We were not
able to detect IGFBP-5 protein in the placenta by West-
ern blotting.
Embryonic gene expression
As in the placentae, embryonic mRNA levels of β-actin
did not differ between genotypes (F(1,19) = 0.29, P = 0.60)
and so this gene was used for standardizing samples. We
did not detect a significant difference between genotypes
in embryonic PAPPA2 mRNA levels (F(1,25) = 0.16, P =
0.69). Levels of PAPPA2 mRNA were much lower in the
embryo (Ct values 21-29) than in the placenta (Ct values
18-25), and PAPPA2 protein could not be consistently
detected in embryos by Western blotting.
Phenotypic outcomes
There was no significant effect of genotype on embryonic
(F(1,25) = 2.08, P = 0.16; Table 2) or placental (F(1,24) = 0.13,
P = 0.72; Table 2) weight at E12.5 or the numbers of
embryos (F(1,25) = 0.15, P = 0.71; Table 2) and spontaneous
abortions (F(1,25) = 1.67, P = 0.21; Table 2).
Our line of mice breeds poorly, and of 33 females
mated, only 17 produced live pups within two months of
mating. The proportion of females that produced pups
within two months did not differ between genotypes; 11
of 23 (48%) C57BL/6 genotype females produced pups,Wagner and Christians Reproductive Biology and Endocrinology 2010, 8:90
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whereas 6 of 10 (60%) DBA/2 genotype females produced
pups (χ2
1 = 0.41; P = 0.52). There were additional matings
that were not allowed to proceed for 2 months, in which
some females produced pups, and since females from
these matings are not included in the above calculations,
these sample sizes are slightly different from those
reported for newborn mass.
There was no significant difference in birth weight
between genotypes, regardless of whether we compared
mean birth weight per female (F(1,19) = 1.30, P = 0.27), or
performed a two-way ANOVA including genotype and
female identity as factors, and used the mean sum of
squares for female identity as the denominator when test-
ing the effect of genotype (F(1,19) = 1.06, P = 0.32; Table 2,
Fig. 3). Litter size at birth did not differ between geno-
types (F(1,19) = 0.37, P = 0.55; Table 2), consistent with the
lack of a difference in the number of embryos in females
collected at embryonic day 12.5. We also measured birth
weight in litters produced by heterozygous parents in
which QTL genotype segregated within litters, and again
found no effect of genotype (F(2,18) = 1.06, P = 0.37; Fig. 3).
We did not find any correlations between placental
PAPPA2 mRNA or protein expression levels and placen-
tal mass (PAPPA2 mRNA r = 0.01, P = 0.97; PAPPA2 pro-
tein r = -0.29, P = 0.21) or embryonic mass (PAPPA2
mRNA r = 0.33, P = 0.10; PAPPA2 protein r = 0.28, P =
0.24).
Discussion
In this study, we demonstrate that a QTL previously
shown to affect postnatal growth in mice also affects the
placental, but not embryonic, expression of PAPPA2. The
placentae of C57BL/6 genotype mice exhibit a 2.5-fold
higher expression of PAPPA2 mRNA than the placentae
of DBA/2 genotype mice, and this difference is reflected
in PAPPA2 protein expression. PAPPA2 presumably
increases the local bioavailability of IGF-II via inactiva-
tion of IGFBP-5, although there are other mechanisms of
IGFBP-5 action [22]. We could not observe this directly
since IGFBP-5 protein levels were too low to be detected
by Western blotting. Since IGF-II promotes growth, we
would expect that increased levels would result in the
promotion of growth in the placenta and therefore
increased birth weight. However, despite a significant dif-
ference in placental PAPPA2 protein expression, we did
not find any significant difference between genotypes in
placental or embryonic weight at E12.5, or birth weight.
We also failed to detect any difference in the placental
mRNA levels of a closely related gene, PAPPA, suggesting
that the expression of the latter gene is not altered to
compensate for differences in PAPPA2 expression. The
mRNA levels of PAPPA2's substrate, IGFBP-5, were not
altered in the placenta in response to changes in PAPPA2
expression, suggesting a lack of feedback in this pathway.
In contrast, Nishizawa et al. [18] observed increased
IGFBP-5 mRNA levels in association with increased
Table 2: Effects of QTL genotype on placental and embryonic gene expression and weight, birth weight and litter size
C57BL/6 DBA/2 P-value
Placental gene expression N = 9 N = 17
PAPPA2 mRNA 2.8 ± 0.2 1.1 ± 0.2 < 0.0001
PAPPA2 proteina 1.5 ± 0.2 0.6 ± 0.2 0.003
PAPPA mRNA 2.3 ± 0.6 1.8 ± 0.5 0.46
IGFBP-5 mRNA 1.5 ± 0.4 1.6 ± 0.3 0.78
Embryonic gene expression N = 9 N = 17
Embryonic PAPPA2 mRNA 0.8 ± 0.1 0.8 ± 0.1 0.69
Phenotypic outcomes N = 10 N = 16
Placental mass at E12.5 (g) 0.084 ± 0.007 0.087 ± 0.005 0.72
Embryonic mass at E12.5 (g) 0.091 ± 0.004 0.083 ± 0.003 0.16
Number of embryos at E12.5 3.8 ± 0.5 4.1 ± 0.4 0.71
Number of spontaneous abortions at E12.5 1.5 ± 0.3 0.9 ± 0.3 0.21
Birth weight (g)b 1.38 ± 0.03 1.31 ± 0.04 0.32
Litter sizeb 3.2 ± 0.5 3.8 ± 0.7 0.55
mRNA and protein levels are expressed relative to reference samples run in each assay
Values are least squares means ± standard error
aSample sizes were reduced for PAPPA2 protein measurements (to 9 C57BL/6 and 11 DBA/2) because some females carried only one embryo 
and placenta, which were used for mRNA quantification
bBirth weight and litter size were measured in 58 C57BL/6 genotype pups from 13 females and in 30 DBA/2 pups from 8 femalesWagner and Christians Reproductive Biology and Endocrinology 2010, 8:90
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PAPPA2 levels in pre-eclampsia. A potential explanation
for this discrepancy could be that PAPPA2 mRNA
expression responds to altered IGFBP-5 protein expres-
sion, but IGFBP-5 mRNA does not respond to altered
PAPPA2 protein expression. We were not able to detect
IGFBP-5 protein by Western blotting, but such data
would have little effect on our conclusions; we would
expect to observe lower IGFBP-5 protein levels in associ-
ation with elevated PAPPA2 expression, but failure to
detect a significant difference would not provide evidence
that IGFBP-5 levels were not affected.
Four recent studies have shown that PAPPA2 levels are
elevated in the serum and placentae of mothers with pre-
eclampsia and HELLP [17-20]. The magnitude of the dif-
ference in PAPPA2 levels between normotensive and
hypertensive pregnancies ranged from approximately 2.5-
[20] to 3-fold [17-19]. We observed a similar degree of
variation between genotypes in our study, and yet we did
not observe any phenotypic effects that would suggest
abnormal placental function. This suggests that the
a l t e r e d  e x p r e s s i o n  o f  P A P P A 2  f o u n d  i n  r e c e n t  h u m a n
studies is not the cause of the pregnancy complications.
Instead, PAPPA2 may be upregulated to compensate for
the abnormal placentation found in pre-eclamptic preg-
nancies, since its upregulation would be expected to pro-
mote placental growth. A previous study by Nishizawa et
al. [18] demonstrated an inverse correlation between
maternal serum PAPPA2 levels and birth weight and
between maternal serum PAPPA2 levels and placental
weight in a population including both normotensive and
pre-eclamptic pregnancies; however, they did not find a
correlation within groups.
Our observation that a substantial alteration in placen-
tal PAPPA2 mRNA and protein expression has no detect-
able effect on birth weight suggests redundancy within
the IGF pathway. Previous studies using PAPPA knock-
outs have shown that the ablation of PAPPA function in
Figure 1 Effect of QTL genotype on relative expression levels of 
placental PAPPA2 mRNA at day 12.5 post-coitum. Quantitative RT-
PCR was used to measure levels of PAPPA2 mRNA in mice homozy-
gous for the C57BL/6 (N = 9) or DBA/2 (N = 17) QTL genotype, and a 
significant difference between genotypes was observed (F(1,24) = 39.8, 
P < 0.0001). Expression levels are relative to those of the reference sam-
ple and are standardized to β-actin.
Figure 2 Effect of QTL genotype on placental PAPPA2 protein ex-
pression at day 12.5 post-coitum. Western blot of 8 representative 
samples of C57BL/6 (C) and DBA/2 (D) genotype placentae. The nitrocel-
lulose membrane was scanned for fluorescence at 700 and 800 nm si-
multaneously. Fluorescence at 700 nm is shown in red and corresponds 
to actin (approximately 40 kDa) whereas fluorescence at 800 nm is 
shown in green and corresponds to PAPPA2 (approximately 250 kDa).
Figure 3 Effect of QTL genotype on birth weight. Left panel: Birth 
weight in litters that do not segregate for the QTL, produced by mat-
ings between homozygous parents. Right panel: Birth weight in litters 
that segregate for the QTL, produced by matings between heterozy-
gous parents. Crosses represent individual pups, and circles represent 
the average litter mass per female. Average masses are not shown for 
segregating litters because they contain pups of more than one geno-
type.Wagner and Christians Reproductive Biology and Endocrinology 2010, 8:90
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mice results in a 40% decrease in birth weight compared
to wild-type littermates [30]. However, PAPPA expression
is low in the murine placenta [31,32], so the observed
d e c r e a s e  i n  b i r t h  w e i g h t  w a s  l i k e l y  d u e  t o  t h e  l a c k  o f
PAPPA expression in the embryo. Our mouse model
showed variation in expression of PAPPA2 in the placenta
but not the embryo, allowing us to examine the impor-
tance of placental PAPPA2 expression independent of
that in the embryo.
A disintegrin and metalloproteinase 12 (ADAM12) is
another metalloproteinase which is involved in the IGF
axis, is highly expressed in placental tissue [33], and
cleaves both IGFBP-3 and IGFBP-5 [34,35]. As with
PAPPA, abnormally low levels of ADAM12 in the mater-
nal circulation in the first trimester are associated with
pre-eclampsia and IUGR [12,36]. Conversely, very high
ADAM12 levels in the first trimester are associated with
high birth weight [12]. However, mice deficient in
ADAM12 have decreased viability, but have no major
morphological abnormalities and are otherwise normal
[37], consistent with the view that there is redundancy
within the IGFBP pathway.
Few studies have examined the expression of PAPPA2
in any tissue; four papers have found differential expres-
sion between placentae of normotensive and hyperten-
sive pregnancy [17-20], one has examined the proteolytic
activity of circulating PAPPA2 [16], and one has com-
pared PAPPA2 expression in the placentae of mice and
humans [23]. In the present study, we found a difference
in placental but not embryonic expression of PAPPA2,
suggesting that there are tissue-specific regulatory ele-
ments involved in the control of PAPPA2 expression. Fur-
ther research should examine the factors that regulate
PAPPA2 in the placenta, and why PAPPA2 is upregulated
during pre-eclampsia. While disregulation of PAPPA2
may not cause pregnancy complications, the factors that
control its expression and cause it to be upregulated in
pre-eclampsia may play a causative role in placental
pathology. Understanding the regulation of PAPPA2 will
help us understand the molecular causes of pre-eclamp-
sia and possibly other pregnancy complications such as
IUGR.
Conclusions
Despite a significant difference between genotypes in pla-
c e n t a l  P A P P A 2  e x p r e s s i o n  s i m i la r  i n  m a gn i t u d e  t o  t h e
difference between pre-eclamptic and normal placentae
previously reported, we observed no difference in embry-
onic or birth weight. Our results suggest that elevated
PAPPA2 levels are a consequence, rather than a cause, of
pregnancy complications.
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